AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03173703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant the XenoSure patch
Description: The LeMaitre XenoSure patch will be used when close the repaired vessel
Study NCT03173703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair/reconstruction of the diseased vessel
Description: The diseased vessel is surgically repaired such as removing the clots.
Study NCT03173703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair/reconstruction of the diseased vessel
Description: The diseased vessel is surgically repaired such as removing the clots.
Study NCT03173703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant the Vascular-Patch
Description: The B. Braun Vascular-Patch will be used when close the repaired vessel
Study NCT03569267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLX10010
Description: A cell penetrating asymmetric siRNA (cp asiRNA)
Study NCT03569267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02978222 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FRα peptide plus Adjuvant (GM-CSF)
Description: Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
Study NCT02978222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant (GM-CSF) Alone
Description: Intradermal injection 125 μg GM-CSF
Study NCT04713943 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: >Your< Iron Syrup
Description: Once daily dose of >Your\< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks
Study NCT04713943 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Once daily dose of placebo syrup for 12 weeks
Study NCT03476044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
Study NCT03476044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
Study NCT02351362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Group
Description: A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
Study NCT03711383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin and Resistant Starch
Description: 12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
Study NCT03711383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: 12g per inulin in combination with maltodextrin per day the day before the CID
Study NCT03711383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isocaloric maltodextrin before test day
Study NCT01588223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipid identification
Description: The lipids are identified using Mass Spectrometry
Study NCT05859087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Bedside pregnancy intention screening and family planning counseling with offer of bedside contraception initiation.
Study NCT05859087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flyer
Description: Handing flyer to patient that discusses the importance of talking with their doctor about pregnancy intention and contraception use.
Study NCT02938182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: clopidogrel troche 75 mg daily for three months
Study NCT02601417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ignoring result of bile culture
Description: the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group
Study NCT03932526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine + placebo
Description: Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
Study NCT03932526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine + Apatinib
Description: Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
Study NCT04151108 — intervention group
Intervention type: OTHER
Intervention: Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers
Description: Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia (SARC-F), malnutrition (SNAQ), cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, muscle strength, and body composition (BIA)
Study NCT00924625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
Study NCT00924625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volitional exercises
Description: The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
Study NCT00559182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK-8033
Description: MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at \~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).~Enrollment in Parts A and B has been completed.
Study NCT00559182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK-8033 +/- omeprazole
Description: Part C will occur at only one of the investigational sites.~In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.~Enrollment for Part C has been suspended.
Study NCT00781352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrous oxide
Description: 65% nitrous oxide administered during surgery
Study NCT00781352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrogen
Description: Nitrogen administration during surgery
Study NCT02829541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB068
Description: Administered as specified in the treatment arm.
Study NCT02829541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study NCT02963844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Study NCT02963844 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training Sham
Study NCT04108351 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement
Study NCT04108351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement
Study NCT04108351 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Car-following test
Description: Intervention Description: Driving with simulator program for DCV measurement
Study NCT04108351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Car-following test
Description: Intervention Description: Driving with simulator program for DCV measurement
Study NCT04108351 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement
Study NCT04108351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement
Study NCT01389063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
Study NCT01625195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega-3 fatty acid supplementation
Description: This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
Study NCT01625195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: corn/soybean oil placebo
Description: This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4x 1285 mg capsules/d, two capsulesat breackfast and two capsules at dinner. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials.
Study NCT02961855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anesthesics plus antiinflammatory, CLIFE1
Description: anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
Study NCT02961855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesics, CLIFE2
Description: local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
Study NCT02774265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VTE prophylaxis with Enoxaparin 30mg BID
Description: Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
Study NCT02774265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VTE prophylaxis with Aspirin 81mg BID
Description: Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
Study NCT02291224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive multimedia platform
Description: An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
Study NCT02291224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm counseling
Description: Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.
Study NCT02291224 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care counseling
Description: Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
Study NCT01597115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duplex ultrasonography
Study NCT03726554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comprehensive Reverse Porous Augmented Glenoid
Description: Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.
Study NCT03726554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comprehensive Mini Humeral Tray
Description: The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
Study NCT00935155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Westerns style acupuncture. Twice a week for 12 weeks
Study NCT00935155 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: Coordination, mobilizing, endurance, strength
Study NCT04151108 — intervention group
Intervention type: OTHER
Intervention: Development of a risk assessment tool for loss of muscle mass and physical function based on clinical and functional measures and systemic biomarkers
Description: Blood tests, frailty (CSHA Clinical Frailty Scale), Early Warning Score (EWS), cognitive status, sarcopenia (SARC-f), malnutrition (SNAQ), comorbidity (Charlson comorbidity Index), polypharmacy, physical function, physical performance, and body composition (BIA)
Study NCT02890719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/day
Description: Grazoprevir 100 mg/ day 12 weeks
Study NCT02890719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/d
Description: Elbasvir 50 mg/day 12 weeks
Study NCT03354793 — intervention group
Intervention type: OTHER
Intervention: Survey on first pregnancy after endometriosis diagnosis
Description: Obstetric complications were noted
Study NCT03354793 — intervention group
Intervention type: OTHER
Intervention: Survey on first pregnancy
Description: Obstetric complications were noted
Study NCT01903252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP05
Description: 3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
Study NCT01903252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol 400 mg
Description: 3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
Study NCT00124839 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
Study NCT03033433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCB-DM101
Description: determination of optimal dose for Stage 2
Study NCT02726399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
Study NCT02890719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/day
Description: Grazoprevir 100 mg/day 16 weeks
Study NCT02890719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/day
Description: Elbasvir 50 mg/d 16 weeks
Study NCT02890719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 1200 mg/day
Description: Ribavirin 1200 mg/day 16 weeks
Study NCT02832089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral carvedilol
Description: oral carvedilol in escalating doses for reducing ventricular rate in AF patients
Study NCT02207907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate plus sodium fluoride
Description: Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
Study NCT02207907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride
Description: Toothpaste containing 1100 ppm fluoride as sodium fluoride
Study NCT00215930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
Study NCT00215930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
Study NCT00215930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.
Study NCT00215930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve \[AUC\] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.
Study NCT02844790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
Study NCT03415165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: green tea buccal tablet
Description: buccal tablet for 8 hrs 3 times aday
Study NCT03415165 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Corticosteroids Topical
Description: kenacort in orabase 4 times aday
Study NCT01079767 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: temsirolimus
Study NCT00850252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifeline
Description: Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
Study NCT02215759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 TA
Study NCT02215759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo